Search Results - "Baguley, Bruce"

Signaling Pathways in Melanogenesis by D'Mello, Stacey A N, Finlay, Graeme J, Baguley, Bruce C, Askarian-Amiri, Marjan E

“…Melanocytes are melanin-producing cells found in skin, hair follicles, eyes, inner ear, bones, heart and brain of humans. They arise from pluripotent neural…”
Get full text

Multiple Drug Resistance Mechanisms in Cancer by Baguley, Bruce C

“…Multiple drug resistance (multidrug resistance; MDR), a phenomenon whereby human tumours that acquire resistance to one type of therapy are found to be…”
Get full text

Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer by Askarian-Amiri, Marjan E, Seyfoddin, Vahid, Smart, Chanel E, Wang, Jingli, Kim, Ji Eun, Hansji, Herah, Baguley, Bruce C, Finlay, Graeme J, Leung, Euphemia Y

“…The transcription factor SOX2 is essential for maintaining pluripotency in a variety of stem cells. It has important functions during embryonic development, is…”
Get full text

Epigenetic regulation in human melanoma: past and future by Sarkar, Debina, Leung, Euphemia Y, Baguley, Bruce C, Finlay, Graeme J, Askarian-Amiri, Marjan E

“…The development and progression of melanoma have been attributed to independent or combined genetic and epigenetic events. There has been remarkable progress…”
Get full text

Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance by Baguley, Bruce C

“…The mechanisms by which tumor cells resist the action of multiple anticancer drugs, often with widely different chemical structures, have been pursued for more…”
Get more information

DNA-Binding Anticancer Drugs: One Target, Two Actions by Baguley, Bruce C, Drummond, Catherine J, Chen, Ying Yi, Finlay, Graeme J

“…Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in…”
Get full text

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer by McKeage, Mark J, Baguley, Bruce C

“…The unique characteristics of tumor vasculature represent an attractive target that may be exploited by vascular-targeting anticancer agents. A promising…”
Get full text

Optimization of the formation of embedded multicellular spheroids of MCF-7 cells: How to reliably produce a biomimetic 3D model by Zhang, Wenli, Li, Caibin, Baguley, Bruce C., Zhou, Fang, Zhou, Weisai, Shaw, John P., Wang, Zhen, Wu, Zimei, Liu, Jianping

“…To obtain a multicellular MCF-7 spheroid model to mimic the three-dimensional (3D) of tumors, the microwell liquid overlay (A) and hanging-drop/agar (B)…”
Get full text

Disrupting tumour blood vessels by Tozer, Gillian M, Kanthou, Chryso, Baguley, Bruce C

“…Low-molecular-weight vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumours, resulting in extensive tumour-cell necrosis,…”
Get full text

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines by Leung, Euphemia Y, Askarian-Amiri, Marjan, Finlay, Graeme J, Rewcastle, Gordon W, Baguley, Bruce C

“…The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT, is an attractive therapeutic target in breast cancer…”
Get full text

Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer by Singleton, Dean C, Dechaume, Anne-Lise, Murray, Pamela M, Katt, William P, Baguley, Bruce C, Leung, Euphemia Y

“…Glutamine serves as an important nutrient with many cancer types displaying glutamine dependence. Following cellular uptake glutamine is converted to glutamate…”
Get full text

Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma by Burd, Christin E, Liu, Wenjin, Huynh, Minh V, Waqas, Meriam A, Gillahan, James E, Clark, Kelly S, Fu, Kailing, Martin, Brit L, Jeck, William R, Souroullas, George P, Darr, David B, Zedek, Daniel C, Miley, Michael J, Baguley, Bruce C, Campbell, Sharon L, Sharpless, Norman E

“…NRAS mutation at codons 12, 13, or 61 is associated with transformation; yet, in melanoma, such alterations are nearly exclusive to codon 61. Here, we compared…”
Get more information

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types by Jamieson, Stephen, Flanagan, Jack U, Kolekar, Sharada, Buchanan, Christina, Kendall, Jackie D, Lee, Woo-Jeong, Rewcastle, Gordon W, Denny, William A, Singh, Ripudaman, Dickson, James, Baguley, Bruce C, Shepherd, Peter R

“…Genetic alterations in PI3K (phosphoinositide 3-kinase) signalling are common in cancer and include deletions in PTEN (phosphatase and tensin homologue deleted…”
Get more information

Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration by Jin, Ya, Wu, Zimei, Li, Caibin, Zhou, Weisai, Shaw, John P., Baguley, Bruce C., Liu, Jianping, Zhang, Wenli

“…Purpose To enhance therapeutic efficacy and prevent phlebitis caused by Asulacrine (ASL) precipitation post intravenous injection, ASL-loaded hybrid micelles…”
Get full text

Multidrug resistance in cancer by Baguley, Bruce C

“…It is becoming increasingly clear that the proliferation of human tumours is driven by a small proportion of cells, termed tumour stem cells, which have the…”
Get more information

Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery by Ganta, Srinivas, Paxton, James W., Baguley, Bruce C., Garg, Sanjay

“…Asulacrine (ASL) is an inhibitor of topoisomerase II, which has shown potential against breast and lung cancer. It is a poorly water soluble drug. To allow…”
Get full text

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK by Tran, Khanh B, Kolekar, Sharada, Jabed, Anower, Jaynes, Patrick, Shih, Jen-Hsing, Wang, Qian, Flanagan, Jack U, Rewcastle, Gordon W, Baguley, Bruce C, Shepherd, Peter R

“…The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. Given the high degree of genetic heterogeneity in melanoma, we sought to…”
Get full text

Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation by Zhang, Wenli, Wang, Guangji, See, Esther, Shaw, John P, Baguley, Bruce C, Liu, Jianping, Amirapu, Satya, Wu, Zimei

“…The ultimate aim of this study was to develop asulacrine (ASL)-loaded long-circulating liposomes to prevent phlebitis during intravenous (i.v.) infusion for…”
Get full text

Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing by Sarkar, Debina, Oghabian, Ali, Bodiyabadu, Pasani K, Joseph, Wayne R, Leung, Euphemia Y, Finlay, Graeme J, Baguley, Bruce C, Askarian-Amiri, Marjan E

“…The long non-coding RNA , antisense to the locus, is transcribed from a gene that encompasses multiple disease-associated polymorphisms. Despite the…”
Get full text

Antivascular therapy of cancer: DMXAA by Baguley, Bruce C

“…The vascular endothelium of tumour tissue, which differs in several ways from that of normal tissues, is a potential target for selective anticancer therapy…”
Get more information